Sarepta Therapeutics (SRPT) Misses Q1 EPS by 457c
Tweet
Share
E-mail
Get Alerts SRPT Hot Sheet
Join SI Premium – FREE
(Updated - May 2, 2023 5:18 PM EDT)
Sarepta Therapeutics (NASDAQ: SRPT) reported Q1 EPS of ($5.86), $4.57 worse than the analyst estimate of ($1.29). Revenue for the quarter came in at $253.5 million versus the consensus estimate of $242.4 million.
For earnings history and earnings-related data on Sarepta Therapeutics (SRPT) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Paychex (PAYX) Tops Q1 EPS by 2c
- Scotiabank Reiterates Sector Outperform Rating on Ero Copper Corp. (ERO:CN) (ERO)
- TD Cowen on Alaska Air (ALK): 'Can Alaska ReAccelerate?'
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
